Sweeney Paul, Karashima Takashi, Ishikura Hisashi, Wiehle Sandy, Yamashita Motoyuki, Benedict William F, Cristiano Richard J, Dinney Colin P N
Department of Urology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer Res. 2003 Jul 15;63(14):4017-20.
Successful systemic gene therapy has been hindered by vector-related limitations, including toxicity and inefficient gene delivery to tumor cells after i.v. administration. To circumvent these problems, we developed a novel formulation between the polycation polyethyleneimine and DNA that mediates high-level tumor cell transduction in vitro and efficient i.v. gene delivery in that greater reporter gene expression occurred in tumor than in lung. Strikingly, administration of just 6 micro g of the polyethyleneimine/DNA-p53 vector every 3 days for 3 weeks indicated restoration of normal cell cycle regulation and apoptotic mechanisms as demonstrated by efficient p53 expression, increased apoptosis, and a 70% reduction in tumor size in an orthotopic bladder cancer model. This novel vector formulation represents a new method to increase i.v. delivery of genes to tumors.
成功的全身基因治疗一直受到载体相关限制的阻碍,包括毒性以及静脉内给药后基因向肿瘤细胞递送效率低下。为了规避这些问题,我们开发了一种新型制剂,由聚阳离子聚乙烯亚胺和DNA组成,该制剂在体外介导高水平的肿瘤细胞转导,并在静脉内实现高效的基因递送,因为在肿瘤中报告基因的表达比在肺中更高。引人注目的是,在原位膀胱癌模型中,每3天给予6微克聚乙烯亚胺/DNA-p53载体,持续3周,结果表明通过有效的p53表达、增加的细胞凋亡以及肿瘤大小减少70%,恢复了正常的细胞周期调控和凋亡机制。这种新型载体制剂代表了一种增加基因静脉内递送至肿瘤的新方法。